Certolizumab pegol compared to natalizumab in patients with moderate to severe crohn's disease: Results of a decision analysis

Digestive Diseases and Sciences

Volumn 57, Issue 2, 2012, Pages 472-480

  Ananthakrishnan, Ashwin N ^a,b   Hur, Chin ^a,b   Korzenik, Joshua R ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Certolizumab pegol; Cost effectiveness; Crohn's disease; Natalizumab; Refractory disease; Surgery

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; CROHN DISEASE; DECISION SUPPORT TECHNIQUES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; INTEGRIN ALPHA4; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856749765     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1896-3     Document Type: Article

References (29)

1. BE Sands FH Anderson CN Bernstein, et al. 2004 Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 876 885 14985485 10.1056/NEJMoa030815 1:CAS:528:DC%2BD2cXhsFyitLo%3D (Pubitemid 38252535)
2. SB Hanauer BG Feagan GR Lichtenstein, et al. 2002 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 1541 1549 12047962 10.1016/S0140-6736(02)08512-4 1:CAS:528:DC%2BD38Xkt1Gru70%3D (Pubitemid 34621118)
3. JF Colombel WJ Sandborn P Rutgeerts, et al. 2007 Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 52 65 17241859 10.1053/j.gastro.2006.11. 041 1:CAS:528:DC%2BD2sXit1aqsLw%3D (Pubitemid 46108762)
4. S Schreiber M Khaliq-Kareemi IC Lawrance, et al. 2007 Maintenance therapy with certolizumab pegol for Crohn's disease N Engl J Med 357 239 250 17634459 10.1056/NEJMoa062897 1:CAS:528:DC%2BD2sXotVejs7g%3D (Pubitemid 47080388)
5. JE Gonzaga AN Ananthakrishnan M Issa, et al. 2009 Durability of infliximab in Crohn's disease: a single-center experience Inflamm Bowel Dis 15 1837 1843 19462426 10.1002/ibd.20974
6. F Schnitzler H Fidder M Ferrante, et al. 2009 Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort Gut 58 492 500 18832518 10.1136/gut.2008.155812 1:CAS:528:DC%2BC3cXivFWlsLc%3D
7. JP Gisbert J Panes 2009 Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review Am J Gastroenterol 104 760 767 19174781 10.1038/ajg.2008.88 1:CAS:528:DC%2BD1MXis1artbo%3D
8. WJ Sandborn P Rutgeerts R Enns, et al. 2007 Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Ann Intern Med 146 829 838 17470824 (Pubitemid 351650483)
9. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010;8:688-695 e2.
10. D'Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212.
11. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010;32:384-393.
12. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92-101.
13. WJ Sandborn JF Colombel R Enns, et al. 2005 Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 1912 1925 16267322 10.1056/NEJMoa043335 1:CAS:528:DC%2BD2MXhtF2rsbzF (Pubitemid 41565956)
14. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438-446.
15. MD Silverstein EV Loftus WJ Sandborn, et al. 1999 Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort Gastroenterology 117 49 57 10381909 10.1016/S0016-5085(99)70549-4 1:STN:280:DyaK1MzhsFGmsg%3D%3D (Pubitemid 29297619)
16. Ng SC, Chan FK, Sung JJ. Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:417-427.
17. TA Yousry EO Major C Ryschkewitsch, et al. 2006 Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N Engl J Med 354 924 933 16510746 10.1056/NEJMoa054693 1:CAS:528:DC%2BD28XitVertLs%3D
18. MC Dubinsky E Reyes J Ofman CF Chiou S Wade WJ Sandborn 2005 A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine Am J Gastroenterol 100 2239 2247 16181376 10.1111/j.1572-0241.2005.41900.x 1:CAS:528:DC%2BD2MXhtFGrtL7O
19. -2010 Drug Topics Red Book. PDR Network, LLC, 2010.
20. GG Kaplan C Hur J Korzenik BE Sands 2007 Infliximab dose escalation versus initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Aliment Pharmacol Ther 26 1509 1520 17931345 10.1111/j.1365-2036.2007.03548.x 1:CAS:528:DC%2BD1cXot1yqsw%3D%3D (Pubitemid 350178810)
21. Malone DC, Waters HC, Van Den Bos J, Popp J, Draaghtel K, Rahman MI. A claims-based Markov model for Crohn's disease. Aliment Pharmacol Ther. 2010;32:448-458.
22. WC Winkelmayer MC Weinstein MA Mittleman RJ Glynn JS Pliskin 2002 Health economic evaluations: the special case of end-stage renal disease treatment Med Decis Mak 22 417 430
23. Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010;8:696-702 e1.
24. M Allez K Karmiris E Louis G Van Assche S Ben-Horin 2010 Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects J Crohns Colitis 4 355 366 21122530 10.1016/j.crohns.2010.04.004
25. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228-1239.
26. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574-1582.
27. S Kugathasan SL Werlin A Martinez MT Rivera JB Heikenen DG Binion 2000 Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease Am J Gastroenterol 95 3189 3194 11095340 10.1111/j.1572-0241. 2000.03263.x 1:CAS:528:DC%2BD3cXos1ygsL8%3D
28. I Arijs K Li G Toedter, et al. 2009 Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis Gut 58 1612 1619 19700435 10.1136/gut.2009.178665 1:CAS:528:DC%2BD1MXhs1SjtbjK
29. Arijs I, Quintens R, Lommel LV, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010;16:2090-2098.